These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE. Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870 [Abstract] [Full Text] [Related]
6. Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). Pérez-Belmonte LM, Gómez-Doblas JJ, Millán-Gómez M, López-Carmona MD, Guijarro-Merino R, Carrasco-Chinchilla F, de Teresa-Galván E, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R. J Clin Med; 2018 Sep 11; 7(9):. PubMed ID: 30208631 [Abstract] [Full Text] [Related]
7. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Ledesma G, Umpierrez GE, Morley JE, Lewis-D'Agostino D, Keller A, Meinicke T, van der Walt S, von Eynatten M. Diabetes Obes Metab; 2019 Nov 11; 21(11):2465-2473. PubMed ID: 31297968 [Abstract] [Full Text] [Related]
16. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes. Petite SE, Hill MC. Ann Pharmacother; 2021 Nov 11; 55(11):1326-1332. PubMed ID: 33615832 [Abstract] [Full Text] [Related]
17. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials]. Guo XH, Feng ZK, Xu LH. Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492 [Abstract] [Full Text] [Related]
18. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators. JAMA; 2019 Jan 01; 321(1):69-79. PubMed ID: 30418475 [Abstract] [Full Text] [Related]
19. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Diabetes Care; 2013 Dec 01; 36(12):3875-81. PubMed ID: 24062327 [Abstract] [Full Text] [Related]
20. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. Clin Ther; 2008 Nov 01; 30(11):1976-87. PubMed ID: 19108786 [Abstract] [Full Text] [Related] Page: [Next] [New Search]